Calla Lily Clinical Care Secures $1M to Revolutionize Vaginal Drug Delivery for Fertility and Beyond

In an exciting development for the healthcare and medtech sector, Calla Lily Clinical Care, a British startup at the forefront of innovating drug delivery platforms, has successfully raised £1,000,000 in its latest funding round. This pivotal investment underscores the market’s confidence in Calla Lily Clinical Care's patented, leak-free, and dosage-confident delivery system, designed to revolutionize the administration of vaginally delivered drugs. Initially, the company is focusing on progesterone delivery for miscarriage prevention and IVF support—a segment that has seen a significant increase in demand following the November 2021 update to internationally-renowned NICE's guidance. With an unmet need for patient-friendlier drug administration during the emotionally challenging fertility journey, Calla Lily Clinical Care aims to enhance patient comfort and safety, reducing stress and uncertainty associated with traditional delivery methods. Beyond progesterone, the company is also exploring subsequent therapeutic areas, including treatments for menopause and interventions targeting the vaginal microbiome, demonstrating a broader vision for precision medicine. The recent funding will accelerate clinical trials, support regulatory advancements, and bolster efforts to bring this groundbreaking technology to market, while continuing to uphold the highest standards of safety and efficacy. Notably, the platform has already achieved FDA clearance and earned recognition as one of TIME magazine’s Best Inventions of the Year, further cementing its potential to shape the future of patient-centric care. This infusion of capital not only reinforces Calla Lily Clinical Care’s commitment to innovation but also marks an important milestone in transforming how essential therapies are delivered, marking a new era of convenience and confidence in women's healthcare.